HomePlatform & StrategiesPublications
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor- directed T-cell activation
Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development
Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+tumor-infiltrating lymphocytes
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer
ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models